Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 94

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 94
---
 the Company (article 3c paragraph 1 of the Articles) shall be equal to the maximum amount permitted by law (i.e., in the amount of one -halfof the new share capital to be calculated on the day of the extraordinary shareholders’ meeting less the amount of the conditional share capital for employee and advisory options in accordance with article 3b paragraph 1 of the Articles). 7.To approve the transfer and voting rights limitation of 9.99%, granting the NLS Board discretion to provide for exceptions (article 6 of the Articles). 8.To approve the change of the Company’s name to NewcelX AG and to amend the title and article 1 of the Company’s Articles accordingly. 9.To approve the election of Mr.Ronen Twito as a member and Executive Chairman of the NLS Board and each of Prof. Michel Revel, Mr.Eran Iohan, Ms. Liora Oren and Ms. Tammy Galili to serve as members of the NLS Board for a term lasting until the next annual ordinary shareholders’ meeting of NLS. 10.To approve the election of Mr.Olivier Samuel, Mr.Eran Iohan and Ms. Liora Oren as members of the Compensation, Nomination and Governance Committee for a term lasting until the next annual ordinary shareholders’ meeting. 11.To approve on an advisory basis the appointment of the new senior management of the Company, as follows: Mr.Ronen Twito (Executive Chairman and Chief Executive Officer), Prof. Michel Revel, MD, PhD (Chief Scientific Officer), Mr.Kfir Molakandov PhD (Vice President Research and Development), Mr.Ariel Revel, MD (Director of Medical Affairs) and Dr. Eric Konofal, MD, Ph.D. (Head of DOXA program). 5 12.1. (i) To approve a new maximum aggregate amount of CHF 200,000 (cash based compensation including all applicable social security contributions) for the fixed compensation of the Board of Directors, (ii) to approve the grant of equity or equity linked instruments with maximum aggregate amount of C HF 350,000(equity or equity linked instruments including all applicable social security contributions) for the compensation of Board of Directors and (iii) to approve the participation in the purchase of a run -offinsurance policy for the members of the Board of Directors, to be effective at the time of the Merger’s completion, with coverage amounts and terms to be approved by the Board of Directors,